Xiamen Comfort Science - Public Comps and Valuation Multiples

Xiamen Comfort Science Overview

About Xiamen Comfort Science

Xiamen Comfort Science and Technology Group Co Ltd is a China based company operating in the industries of health massage, health environment, home medical care, and others. The company is principally engaged in manufacturing massage healthcare product like massage chairs. It also offers products in the areas of healthy environment like humidifier, and health monitoring like weight analysis device. The company sells its products in China and other international countries. Some of the company's brands are Ogawa, Cozzia, Fuji, Fujimedic, and Medisana.

Founded

1996

HQ

Employees

n/a

Website

easepal.com.cn

Sectors

Leisure & Recreation

Financials

Last FY Revenue $677M

Last FY EBITDA $57.2M

EV

$584M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Xiamen Comfort Science Financials

See Xiamen Comfort Science valuation multiples based on analyst estimates

Xiamen Comfort Science P&L

In the most recent fiscal year, Xiamen Comfort Science reported revenue of $677M and EBITDA of $57.2M.

Xiamen Comfort Science expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Xiamen Comfort Science valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$677M	XXX	XXX	XXX
Gross Profit	XXX	$244M	XXX	XXX	XXX
Gross Margin	XXX	36%	XXX	XXX	XXX
EBITDA	XXX	$57.2M	XXX	XXX	XXX
EBITDA Margin	XXX	8%	XXX	XXX	XXX
EBIT	XXX	$12.4M	XXX	XXX	XXX
EBIT Margin	XXX	2%	XXX	XXX	XXX
Net Profit	XXX	$9.0M	XXX	XXX	XXX
Net Margin	XXX	1%	XXX	XXX	XXX
Net Debt	XXX	$46.8M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Xiamen Comfort Science including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Xiamen Comfort Science achieved $677M in revenue and $57.2M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$677M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$244M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	36.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$57.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	8.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$12.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	1.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$9.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	1.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$46.8M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Xiamen Comfort Science

This financial data table provides comprehensive performance metrics for Xiamen Comfort Science, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Xiamen Comfort Science reported $677M in total revenue.
Fiscal year EBITDA was $57.2M.
The company maintained a gross profit margin of 36.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 8.4%.
Net profit margin reached 1.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Xiamen Comfort Science. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Xiamen Comfort Science Stock Performance

Xiamen Comfort Science has current market cap of CNY 4.2B (or $583M), and EV of CNY 4.2B (or $584M).

Market Cap Evolution

Xiamen Comfort Science Stock Data

As of September 30, 2025, Xiamen Comfort Science's stock price is CNY 7 (or $1).

See Xiamen Comfort Science trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$584M	$583M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Xiamen Comfort Science Valuation Multiples

Xiamen Comfort Science's trades at 0.9x EV/Revenue multiple, and 10.2x EV/EBITDA.

See valuation multiples for Xiamen Comfort Science and 15K+ public comps

Xiamen Comfort Science Financial Valuation Multiples

As of September 30, 2025, Xiamen Comfort Science has market cap of $583M and EV of $584M.

Equity research analysts estimate Xiamen Comfort Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Xiamen Comfort Science's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$583M	XXX	$583M	XXX	XXX	XXX
EV (current)	$584M	XXX	$584M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	0.9x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	10.2x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	47.0x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	64.7x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-46.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Xiamen Comfort Science Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Xiamen Comfort Science Margins & Growth Rates

Xiamen Comfort Science's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Xiamen Comfort Science's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Xiamen Comfort Science's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Xiamen Comfort Science and other 15K+ public comps

Xiamen Comfort Science Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	7%	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	8%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	-17%	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	10%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	34%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial